Drawing for EGRIFTA MDV

USPTO serial 97285560

EGRIFTA MDV

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
WOOD, DANIEL PAUL
Law office
TMO LAW OFFICE 128

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with EGRIFTA MDV?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sebastian Lovera Riso

Sebastian Lovera Riso LADAS & PARRY LLP1040 AVENUE OF THE AMERICASNEW YORK, NY 10018-3738UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, nonalcoholic steathohepatitis and nonalcoholic fatty liver diseaseACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
May 18, 2025MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
May 18, 2025ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jan 19, 2025GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jan 19, 2025GNSIINQUIRY TO SUSPENSION E-MAILED—
Jan 19, 2025CNSISUSPENSION INQUIRY WRITTEN—
Jan 14, 2025RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Feb 12, 2024GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Feb 12, 2024GNSLLETTER OF SUSPENSION E-MAILED—
Feb 12, 2024CNSLSUSPENSION LETTER WRITTEN—
Feb 12, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 12, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 12, 2024ALIEASSIGNED TO LIE—
Sep 21, 2023ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jul 3, 2023GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jul 3, 2023GNSIINQUIRY TO SUSPENSION E-MAILED—
Jul 3, 2023CNSISUSPENSION INQUIRY WRITTEN—
Jun 28, 2023RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Dec 12, 2022GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Dec 12, 2022GNSLLETTER OF SUSPENSION E-MAILED—
Dec 12, 2022CNSLSUSPENSION LETTER WRITTEN—
Dec 8, 2022DOCKASSIGNED TO EXAMINER—
Mar 3, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 1, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance